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ANALISA PROTEOMIK KE ATAS PROSES PEMBENTUKAN KANSER 
PROSTAT TERARUH OLEH HETEROSIKLIK AMIN 2-AMINO-1-METIL-
6-FENILIMIDAZO[4,5-b]PIRIDIN (PhIP) MENGGUNAKAN MODEL IN 
VITRO  
 
ABSTRAK 
2-amino-1-metil-6-fenilimidazo[4-5-b]piridin (PhIP) merupakan penyebab 
kanser daripada kumpulan heterosiklik amin yang paling banyak ditemui dalam 
daging yang dimasak. Objektif kajian ini adalah untuk menyiasat kesan PhIP ke atas 
sel normal prostat manusia, RWPE-1, dalam proses karsinogenesis prostat 
menggunakan dos yang releven kepada manusia, pada peringkat sel dan protein. Sel 
prostat RWPE-1 didedahkan dengan kepekatan PhIP 10
-7
, 10
-8
, 10
-9
 atau 10
-10
 M, 
yang dilarut dalam pelarut DMSO dengan kepekatan 0.003%, 0.025% atau 0.25% 
dengan kehadiran/tanpa sistem pengaktifan metabolik. Kaedah-kaedah yang 
digunakan dalam kajian ini adalah asai MTS untuk ujian kesitotoksikan dan 
proliferasi sel, Alamar Biru untuk ujian proliferasi sel, asai transformasi dan  invasi 
sel, dan proteomik ‘shotgun’. Keputusan yang diperoleh daripada asai kesitotoksikan 
dan proliferasi sel menunjukkan peningkatan dalam kebolehhidupan dan proliferasi 
sel RWPE-1 yang dirawat dengan semua kepekatan PhIP dalam semua kepekatan 
DMSO dengan kehadiran sistem pengaktifan metabolik, dimana semakin rendah 
kepekatan DMSO, semakin tinggi tindakbalas yang berlaku. Dalam asai transformasi 
sel menggunakan parameter yang sama dengan asai sebelumnya, keputusan 
menunjukkan semua kumpulan rawatan PhIP dengan kehadiran sistem pengaktifan 
metabolik mengalami perubahan neoplastik dimana sel-sel tersebut menunjukkan 
pertumbuhan pengankoran tak bersandar iaitu keupayaan untuk membiak di atas 
xx 
 
lapisan agar dan membentuk koloni. Pembiakan semula koloni-koloni sel RWPE-1 
ini menunjukkan perubahan tambahan dalam tingkahlaku pertumbuhan sel bagi 
kumpulan yang dirawat dengan PhIP pada kepekatan 10
-7
M dalam larutan DMSO 
0.003% yang mempamerkan keupayaan untuk membiak yang paling tinggi 
berbanding kumpulan lain. Penilaian lanjut dalam asai invasi sel menunjukkan sel-sel 
kumpulan ini tidak dapat bergerak menembusi lapisan matrigel, menunjukkan 
kemungkinan sel-sel ini masih berada diperingkat awal transformasi. Keputusan 
ujian pengecaman protein menunjukkan sebanyak 41 protein dikenalpasti dalam 
kumpulan kawalan dan 81 protein dalam kumpulan rawatan. Analisis famili protein 
menunjukkan terdapat 11 famili berada dalam kedua-dua sampel manakala 24 famili 
hanya terdapat didalam kumpulan rawatan. Pengiraan peptida menggunakan 
intrumentasi aplikasi pengiraan tanpa label PEAKS gagal memberikan sebarang 
keputusan. Namun, kajian ilmiah yang meluas menunjukkan semua protein yang 
dikenalpasti dalam kumpulan rawatan telah dilaporkan mempunyai kaitan dengan 
kanser prostat. Analisis anotasi protein menunjukkan anotasi yang lebih banyak bagi 
kumpulan rawatan dalam semua kategori; persetempatan sel, proses biologi dan 
fungsi molekul. Analisis pengayaan laluan telah mengenalpasti pengayaan beberapa 
laluan yang diketahui terlibat dalam proses kanser. Kesimpulannya, semua keputusan 
menunjukkan  sel RWPE-1 yang dirawat dengan PhIP dalam kehadiran sistem 
pengaktifan metabolik pada dos yang  releven bagi manusia, terutamanya dos 10
-7
M 
dalam 0.003% DMSO, mempamerkan peringkat awal transformasi neoplastik pada 
peringkat sel dan protein dalam karsinogenesis prostat, manakala keputusan analisa 
proteomik menunjukkan semua protein yang dikenalpasti dalam kumpulan rawatan 
mempunyai potensi untuk kajian seterusnya bagi menentukan peranan dan 
sumbangan protein-protein ini dalam kanser prostat.   
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PROTEOMIC ANALYSIS OF PROSTATE CARCINOGENESIS INDUCED 
BY HETEROCYCLIC AMINE 2-AMINO-1-METHYL-6-
PHENYLIMIDAZO[4,5-b]PYRIDINE (PhIP) USING IN VITRO MODEL 
 
ABSTRACT 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is the most 
abundant type of carcinogenic heterocyclic amine produced in cooked meat. This 
study aims to investigate the carcinogenic effect of human physiologically relevant 
concentration of PhIP on human prostate epithelial cell line, RWPE-1, at cellular and 
protein levels in prostate carcinogenesis. RWPE-1 cells were exposed to 10
-7
, 10
-8
, 
10
-9
 or 10
-10
 M PhIP, diluted in 0.003%, 0.025% or 0.25% DMSO, with or without 
metabolic activation system. The methodologies used in this study were MTS assay 
for cytotoxicity and cell proliferation tests, Alamar Blue assay for cell proliferation 
test, cell transformation assay, invasion assay and shotgun proteomic. In cytotoxicity 
and cell proliferation assays, results showed that the viability and proliferation of 
RWPE-1 cells treated with PhIP at all doses in all DMSO concentrations in the 
presence of metabolic activation system were increased depending on the vehicle 
concentration, where the lower the concentration of the vehicle used, the higher the 
cellular responses observed. In the cell transformation assay conducted using the 
same experimental settings as the previous assays, the results showed that all PhIP-
treated groups with metabolic activation system exhibited neoplastic transformation 
characteristic as these transformed cells showed anchorage-independent growth 
growing above the agar layer and formed colonies in soft agar. Subsequent re-plating 
of these colonies showed that only RWPE-1 cells treated with 10
-7
M PhIP in 0.003% 
DMSO showed additional changes in growth behaviour exhibiting the highest 
xxii 
 
proliferative activity compared to other groups. Further evaluation of this group in 
cell invasion assay revealed that the cells were unable to migrate through the 
matrigel barrier into secondary sites signifying a high possibility that the cells were 
in the early stage of transformation. Protein identification results showed 43 and 81 
proteins identified in control and PhIP-treated samples, respectively. Analyses of the 
protein families’ abundance for both samples revealed 11 protein families in both 
samples whereas 24 protein families were exclusively identified in PhIP-treated 
RWPE-1 cells. Peptide quantification using PEAKS label-free quantification tool 
failed to produce any result. However, an extensive literature search revealed that all 
proteins identified in the PhIP-treated RWPE-1 cells have been reported to be 
associated with prostate cancer. Protein annotation analysis presented more 
annotations for PhIP-treated sample in all classifications; the cellular localization, 
biological process and molecular functions. Pathway enrichment analysis identified 
overrepresentation of several pathways which were known to be involved in the 
cancer process. In conclusion, all results obtained indicated that in the presence of 
metabolic activation system, RWPE-1 cells treated with physiologically relevant 
concentration of PhIP, in particular at the dose of 10
-7
M in 0.003% DMSO vehicle 
concentration, exhibited a considerable degree of early neoplastic transformation at 
both the cellular and protein levels in prostate carcinogenesis, whereas the results 
obtained from the proteomic analysis showed that all proteins identified in the PhIP-
treated RWPE-1 cells can be potential candidates for further evaluation of their roles 
and contributions in prostate cancer.   
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 RESEARCH BACKGROUND 
Cancer exacts an overwhelming price on the society as a whole since the burden 
and the devastating effects of this disease affect both the patients and their families 
especially due to the long term curative and palliative treatment regimes which can be 
fairly costly as well as the consequential loss because of morbidity and mortality. For 
decades, both scientists and physicians alike have put tremendous efforts in investigating 
the means to identify various forms of cancer at early stage especially well before they 
become malignant and thus, incurable or fatal. Elucidating and understanding the 
etiology of cancer and the mechanisms involved in the induction and progression of this 
disease at each genetic, molecular and cellular level can substantially aid in devising a 
strategy for early detection, prevention, intervention and therapy.  
According to the International Agency for Research on Cancer, prostate cancer 
was reported to be the second most common cancer among men in the world in 2012 
(Ferlay et al., 2013). About one third (30-35%) of all cancers are caused by dietary 
habits, followed by tobacco smoking (20-30%) and genetic defects (5-10%), while the 
rest are caused by environmental factors and lifestyle (Anand et al., 2008). Many 
epidemiological studies have shown the association of diet and cancer which is mainly 
due to consumption of animal products, in particular cooked meat. Various genotoxic 
and mutagenic compounds have been identified in both processed and cooked food and 
 2 
one of them is the heterocyclic amines (HCA). Cooking of muscle meats and fish will 
result in the production of many different HCA compounds where most of them has 
been associated with the increase of cancer risk as they possess high mutagenic and 
carcinogenic potentials (Sugimura et al., 2004). In general, the HCAs can be divided 
into two groups, polar and non-polar compounds. The former includes  imidazoquinoline 
(e.g. IQ), imidazoquinoxaline (IQx), and imidazopyridine types, whereas the latter have 
a common pyridoindole or dipyridoimidazole group. The most abundant HCAs formed 
is the polar type 2-amino-1-methyl-6-phenylimidazole [4,5-b] pyridine (PhIP). The 
action of PhIP was reported to be organ-specific as it was found to induce tumour 
specifically in the breast, colon, liver and prostate, which are considered to be diet-
related target sites for cancer (Murkovic, 2007; Knize et al., 2002; Sugimura, 2000). The 
IARC (1993) has classified PhIP as Group 2B carcinogen, which is possibly 
carcinogenic to humans. 
Most of the previous in vitro and/or in vivo experiments on PhIP were fairly 
unsuitable to investigate the mechanisms of carcinogenesis in human or to identify 
proteins implicated in this process. Although numerous in vitro studies using 
commercial human cell lines have been reported, most of them do not fully reflect the 
intricate activation and detoxification processes of PhIP in humans. In in vivo studies, 
extrapolating the results of such experiments to humans is not entirely appropriate as 
laboratory animals have different metabolic pathways and capacities than human. In 
addition, the doses investigated in these studies were tens to hundreds times higher than 
the human exposure level. Thus, the question whether humans are exposed to levels of 
PhIP in their diet is sufficient to contribute to the induction of prostate cancer is yet to be 
answered. Moreover, in prostate carcinogenesis, the anatomical location regarding 
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where the carcinogenic process take place in both species is still a debate among the 
scientists. Thus, experimental protocols and models that can somewhat reflect the 
carcinogenic process of PhIP in human are required in order to detect the 
biomarkers/proteins relevant for humans. It is hoped that through this study, the 
carcinogenic effect of PhIP in the prostate carcinogenesis can be understood and 
investigated. 
  
1.2 GENERAL OBJECTIVE 
The general objective of this study is to investigate the carcinogenic effect of 
human physiologically relevant concentration of PhIP on normal human prostate 
epithelial cell line at cellular and protein levels in prostate carcinogenesis. 
 
1.3 SPECIFIC OBJECTIVES 
1.3.1  To determine the cytotoxic effect of PhIP on human prostate epithelial cells. 
1.3.2 To determine the effects of PhIP on proliferative activity of human prostate 
epithelial cells. 
1.3.3 To determine the neoplastic characteristics acquired by human prostate cells 
when treated with PhIP. 
1.3.4 To identify the proteins present in human prostate epithelial cells treated with 
PhIP that can potentially be used as PhIP-induced prostate cancer biomarkers. 
1.3.5 To determine the effect of PhIP on protein expression of human prostate 
epithelial cell line. 
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1.4 HYPOTHESIS 
Human exposure level of PhIP exerts carcinogenic effects on human prostate 
epithelial cell line at the cellular and protein level. 
 5 
CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 CANCER 
2.1.1 Incidences 
Due to the resemblance of appendage-like projections of tumour blood vessels to a 
crab’s body and legs, Hippocrates used the Greek word karkinoma, meaning crab, to 
describe tumours (Doyle & Shaw, 2011; Virshup & McCance, 2008). Today, cancer 
represents a major burden of disease globally and poses a great challenge both to the 
physicians and researchers, yet the etiology and the exact mechanisms of this disease 
remain obscured. Worldwide, International Agency for Research on Cancer (IARC) 
reported 14.1 million new cancer cases, 8.2 million cancer mortality and 32.6 million 
people were living with cancer in 2012 (Ferlay et al., 2013). The Surveillance 
Epidemiology and End Results (SEER) program database by National Cancer Institute 
estimated that in 2017 over 1.6 million will be diagnosed with cancer and 600 920 will 
die from it in United States (Howlader et al., 2018). According to the 5-year report by 
the Malaysian National Cancer Registry, which covers all cancer cases registered by the 
state registries in Malaysia from 2007 to 2011, a total number of 103,507 new cancer 
cases were reported in Malaysia during this period with a total of 64,275 medically 
certified and non-medically certified cancer deaths (Azizah et al., 2016). 
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2.1.2 Carcinogenesis 
Normal cellular physiology is a process which is strictly regulated to ensure balance 
in the cellular multiplication and growth with positive and negative feedback loops. It 
determines the action of a cell whether to differentiate, divide, adapt to its 
microenvironment or commit suicide via apoptosis when necessary (Kyprianou, 2012). 
In adult, this process is generally restricted to the replacement of lost cells and these 
cells normally respect their own place and space in the body’s society of cells. When 
mutations occur within the genes responsible for controlling cell division and growth, a 
normal cell may transform into a pre-neoplastic/neoplastic one (Sherwood, 2001). 
Eradication or inactivation of tumour suppressor proteins and/or the activation of 
oncoproteins will cause the cells to reproduce excessively and/or unable to commit 
suicide. Further division and proliferation of the cells will cause the mutations to 
accumulate. These cells will remain impaired and cancer-related genes may be activated 
when the genes required to repair the damage are disabled (Jain, 2014). This will result 
in imbalances of the regulation of normal physiology causing the cells to become 
oblivious to the control mechanisms normally limiting their growth and subsequently 
giving rise to an abnormal mass of proliferating cells called neoplasm (Kumar et al., 
2013; Sherwood, 2001). These neoplastic cells will occupy the space in the surrounding 
normal tissue, an event called local invasion, resulting in infiltration of local tissue, 
blood vessels and the lymph system (Doyle & Shaw, 2011).  
If the mass is slow growing, persists in its original location, consists of cells that 
remain compacted and encapsulated, does not invade the surrounding tissue/area and 
seldom kill the host if removed before it compresses the vital organ, it is considered 
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benign neoplasm. In contrast, malignant neoplasms consist of transformed cells which 
may multiply rapidly and relentlessly forming a non-encapsulated invasive mass that 
lacks the altruistic behaviour characteristic of normal cells. These malignant cells, 
collectively referred to as cancer, usually resemble immature cells, invade their 
surrounding rather than pushing them aside, do not adhere well to the neighbouring 
normal cells which enable them to escape from the primary mass and migrate via blood 
or lymph to distant organs/sites where they form secondary cancer masses. This aptitude 
to travel, spread and invade other parts of the body is called metastasis (King & Robins, 
2006; Sherwood, 2001; Marieb, 2001). Clinically, cancer is regarded as a group of 
diseases that vary in the age of onset, growth rate, state of cellular differentiation, 
invasiveness and metastatic potential, diagnostic detectability, response to treatment, and 
prognosis (Ruddon, 1995). 
Carcinogenesis, or cancer formation, is a multistep process resulting from 
accumulation of errors in vital regulatory pathways at both phenotypic and genetic levels 
that collectively give rise to the transformed phenotype (Marieb, 2001; King & Robins, 
2006). Although genetic damage lies at the heart of cancer formation, the actual causes 
of cellular alterations that produce a cancer is somewhat elusive. It is well known that 
both internal (e.g. genetic predisposition, defective immune system) and external factors 
(e.g. tobacco, radiation, chemical/medical/occupational carcinogens, viruses, physical 
mutagens, microbial agents and environmental influences) can act as carcinogens 
(Kumar et al., 2013; Doyle & Shaw, 2011; Allen et al., 2005; Campbell and Reece, 
2002; Ruddon, 1995). What these factors have in common is that all of them can cause 
mutations (Marieb, 2001). Formation of tumour does not occur immediately following 
exposure to a carcinogen. This disease usually develops after a long latent period and 
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there are three major stages involved in this process, termed tumour initiation, 
promotion and progression (Figure 2.1) (Grant, 2013; Greenwald, 2008).  
In the initiation stage, a normal cell is converted to an initiated cell in response to 
DNA damaging agents which, if not repaired before the next cell division, would lead to 
erroneous DNA replication resulting in fixation of mutations within the genome of 
individual cells. There are three factors that determine the likelihood of tumour 
initiation: the rate of pro-carcinogen activation, the efficiency and fidelity of DNA repair 
and the capacity for cell proliferation. Although initiation is irreversible, not all initiated 
cells will advance towards becoming a tumour as many of them may die through 
apoptosis. Further proliferation-enhancing signals are also required for the evolvement 
(Grant 2013; Greenwald, 2008). 
The promotion stage is characterized by the transformation of the initiated cells into 
a population of pre-neoplastic cells resulted from alterations in gene expression. This 
phenomenon can be prompted by various tumour-promoting agents that tend to be non-
genotoxic in their own right. The promoters are highly likely to be able to promote 
clonal expansion of initiated cells resulting in the survival and proliferation of pre-
neoplastic cells and the formation of benign lesions. Although most of these lesions may 
regress spontaneously, a few cells may advance into a malignant neoplasm after 
acquiring additional mutations (Grant 2013; Greenwald, 2008; Franks & Knowles, 
2005). 
Tumour progression is the stage whereby the pre-neoplastic cells are converted into 
neoplastic cell populations as a result of further genetic alteration, either spontaneously 
or following additional exposure to carcinogens. It is thought that endogenous elements 
such as hormones, growth factors, nutrients, cell growth, and other common cellular 
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processes advance the promoted cancerous cell further (Grant 2013; Greenwald, 2008; 
Franks & Knowles, 2005). Once these cells are promoted into neoplastic cells, they can 
be characterized by ten fundamental functional capabilities that collectively, dictate 
malignant phenotype: genome instability and mutation, resisting cell death, deregulating 
cellular energetics, sustaining proliferative signalling, evading growth suppressors and 
immune destruction, enabling replicative immortality, tumour-promoting inflammation, 
activating invasion and metastasis, and inducing angiogenesis (Hanahan, 2014).  
Cancer causes mortality in most cases for several interrelated reasons. The cancer 
cells crowd out normal cells by robustly contending for space and nutrients with them, 
yet are unable to perform the functions of the cells they are destroying. Cancer cells 
typically remain immature and do not become specialized and as such lack the ability to 
execute the specialized functions of the normal cell type from which they mutated. The 
impacted organs will gradually become disrupted until they are no longer able to 
perform their life-sustaining functions, and death results (Sherwood, 2001). 
 
2.2 PROSTATE GLAND 
2.2.1 Anatomy, Histology and Physiology 
The prostate gland is a single doughnut-shaped gland measuring 4 cm in diameter 
and weighing approximately 20 g (Figure 2.2). Adjacent to the rectum, it encircles the 
part of the urethra just inferior to the bladder. Enclosed by a thick fibroelastic capsule, it 
is made up of 20-30 compound tubuloalveolar glands embedded in a rich fibromuscular 
stroma of smooth muscle and dense connective tissue.  
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Figure 2.1: Sequential model of carcinogenic process divided into three stages; tumour 
initiation, tumour promotion, and tumour progression (extracted from Oliveira et al., 
2007). 
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Septa from this capsule penetrate the gland and divide it into lobes that are indistinct 
in adult men. The prostate has three distinct zones. 25% of the gland is formed by the 
central zone which contains the ejaculatory ducts. The peripheral zone takes up 70% of 
the gland, which occupies the posterolateral region of the prostate whereas the transition 
zone sits near the urethra. The peripheral zone is the major site of prostatic 
adenocarcinomas is found to be most susceptible to neoplastic transformation while 
most benign prostatic hyperplasia originates from the transition zone. Generally, 
carcinoma of the latter zone have been attributed to good prognosis, i.e., low Gleason 
grade, low rates of capsule penetration and margin positivity (True & Vakar-Lopez, 
2011; Nelson & De Marzo, 2007; Marieb, 2001). 
Prostate tissues contain an epithelium, the source of prostatic secretions, and a 
stroma, occupied by fibroblasts, smooth muscle cells, nerves, and blood vessels. The 
prostate epithelium is composed of basal cells, some of which are believed to serve as 
the multipotent epithelial stem cells, luminal/columnar secretory cells, terminally 
differentiated to produce ejaculate secretions, and rare neuroendocrine cells, which are 
found scattered throughout the prostate epithelium in both basal and luminal 
compartment (Nelson & De Marzo, 2007).   
Normal growth and development of the prostate require both androgenic steroids 
and a functioning androgen receptor (AR). Testosterone, produced by Leydig cells in the 
testes, is the major circulating androgenic hormone. An enzyme, 5α-reductase converts 
testosterone to 5α-dihydrotestosterone (DHT), a more potent androgen that can bind 
ARs and promote dissociation of the receptors from chaperone protein (Nelson & De 
Marzo, 2007). The prostatic gland secretion is a thin, milky substance that contains 
citrate (a nutrient source) and several enzymes (fibrinolysin, hyaluronidase, acid  
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Figure 2.2: Anatomy of the adult normal prostate containing several distinct regions, 
including a central zone (CZ), a peripheral zone (PZ), a transitional zone (TZ), and a 
periurethral zone (extracted from Kumar et al., 2013). 
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phosphatase), and prostate-specific antigen  (PSA). This secretion accounts for up to 
one-third of the semen volume and has an alkaline pH that neutralizes the acidic vaginal 
secretion which helps the sperm to survive in the female reproductive tract as sperm are 
more viable in a slightly alkaline environment (Deneris & Huether, 2008; Nelson & De 
Marzo, 2007; Marieb, 2001; Sherwood, 2001). 
2.2.2 Pathophysiology 
There are three major disorders of the prostate gland, namely, prostatitis, 
hyperplastic lesions, and neoplastic disorders, of which prostate cancer is by far the most 
important clinically. Prostatitis is an inflammation of the prostate and typically involves 
some of the gland’s excretory ducts only. Inflammatory processes are manifested by 
infiltration of inflammatory cell in prostate tissue which are either of acute (neutrophilic 
cell-rich) or chronic (mononuclear cell-rich) type. Prostatitis is divided into four 
categories: i) acute bacterial prostatitis, caused by the organisms that are also implicated 
in other urinary tract infections; ii) chronic bacterial prostatitis also caused by common 
uropathogens; iii) chronic nonbacterial prostatitis, in which no uropathogen is identified 
despite the presence of local symptom; and iv) asymptomatic inflammatory prostatitis, 
related with incidental identification of leukocytes in prostatic secretions without 
uropathogens (Epstein, 2013; True & Vakar-Lopez, 2011; Deneris & Huether, 2008). 
Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy, is the 
enlargement of the prostate gland. This condition is a result of an increase in 
stromal:epithelial cell ratio and is typically limited to the transition zone. This may be 
due to proliferation of both stromal and epithelial elements or decreased programmed 
cell death, either which can lead to cellular accumulation resulting in the enlargement of 
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the gland and, in some cases, urinary obstruction. DHT was identified to be the major 
hormonal stimulus for the excessive proliferation. The affected prostate typically weighs 
between 60 to 100 g and contains many well-circumscribed nodules that may appear 
solid or contain cystic spaces, the latter corresponding to dilated glandular elements. 
These nodules compress the periurethral zone and chronic obstruction may result in 
recurrent urinary tract infections. Clinical signs and symptoms include increased 
urgency to urinate, hesitancy during urination, decreased force of urinary stream and 
nocturia (Vuichoud & Loughlin, 2015; Epstein, 2013; True & Vakar-Lopez, 2011; 
Deneris & Huether, 2008). 
 
2.3 PROSTATE CANCER 
2.3.1 Incidences  
Prostate cancer occurs predominantly in men older than 50 years of age (Epstein, 
2013). The incidence intensifies with advancing age where more than 75% of all 
prostate cancer cases are commonly diagnosed in men older than 65 years (Azizah et al., 
2016; Deneris & Huether, 2008). According to IARC, prostate cancer is the second most 
common cancer and the fifth-leading cause of cancer-related mortality among men in the 
world in 2012 (Ferlay et al., 2013). In Malaysia, it was listed as the fifth most frequent 
cancer among men during the period of 2007 to 2011 and more than half of the patients 
were diagnosed at a late stage (stage 3 and 4) as shown in Figure 2.3 (Azizah et al., 
2016). 
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Figure 2.3: (A) Ten most frequent cancers being diagnosed among male population in 
Malaysia for the period of 2007 to 2011 and (B) stages of prostate cancer at diagnosis in 
Malaysia during the same period (Azizah et al., 2016). 
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2.3.2 Histopathology 
Prostate cancer may originate from tumours derived from either the epithelial 
component or the non-epithelial/stromal component. The former can be divided into 
acinar or non-acinar type based on their morphological appearances. The most common 
appearance of epithelial-derived tumours is the acinar type comprising 90% of tumours. 
Some variants under this type include signet ring, atrophic, microacinar and 
pseudohyperplastic. The non-acinar type consists of urothelial carcinoma, ductal and 
sarcomatoid. The non-epithelial/stromal tumours which are the rarer type of prostate 
cancer comprise solitary fibrous tumours and leiomyosarcomas. Squamous cell 
carcinoma and small cell carcinoma are among the less common histological variants 
occurring in prostate cancer. Both of them are associated with aggressive disease, 
hormonal therapy resistance and poor prognosis (Oxley, 2014; Humphrey, 2012). 
Different cell types of origin can undergo oncogenic transformation creating distinct 
subtypes of tumours with specific histopathological and/or molecular features that can 
influence patient responsiveness to treatment and its outcome (Lee & Shen, 2015). 
Acinar-type adenocarcinoma is the predominant histological subtype of prostate cancer 
characterized by rare neuroendocrine cells, luminal secretory cells and an absence of 
basal cells (Stoyanova et al., 2013; Humphrey, 2012). The luminal phenotypic feature of 
prostate adenocarcinoma may imply that either this corresponds to a luminal cell of 
origin or as a result of basal-to-luminal differentiation from basal cell of origin (Lee & 
Shen, 2015; Kwon et al., 2014; Stoyanova et al., 2013). The less common prostate 
cancer variants such as small-cell carcinoma has features such as loss of p53 expression 
and proliferating neuroendocrine cells (Chen et al., 2012); whereas squamous cancers, 
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characterized by basal cells, can occur as squamous cell carcinoma or in the context of 
adenocarcinoma  (Stoyanova et al., 2013; Humphrey, 2012; Parwani et al., 2004). 
Prostate cancer is generally a latent disease as it usually develops slowly and 
dysplastic lesions may take years or even decades before becoming cancer 
(WCRF/AICR, 2014). Some histopathological conditions of the prostate have been 
suggested to give rise to pre-neoplastic lesions. Prostatic intraepithelial neoplasia (PIN) 
is a lesion in which neoplastic prostate epithelial cells appear to proliferate within the 
confines of otherwise normal glandular structure and can be divided into low-grade (LG-
PIN grade 1) and high-grade PIN (HG-PIN grades 2 and 3) (True & Vakar-Lopez, 2011; 
Nelson & De Marzo, 2007). However, only the latter is reported in current practice. In 
LG-PIN, the epithelial cells grow in multiple layers projecting into the lumen of the 
gland with intact basal layer and no increase of serum PSA is noted in this lesion. In 
contrast, this basal layer has been described as incontinuous in HG-PIN. It is associated 
with invasive adenocarcinoma due to its resemblance in the cytological features and 
similarities in many genetic abnormalities. The location of the HG-PIN is similar to that 
of prostate cancer as both reside in the peripheral zone of the prostate (Tuomela & 
Harkonen, 2014; Oxley, 2014; True & Vakar-Lopez, 2011).    
Proliferative inflammatory atrophy (PIA) is another lesion that was suggested as a 
precursor lesion to prostate cancer. Inflammatory processes in the prostate tend to cause 
collateral damage to the surrounding tissue resulting in this specific lesion. PIA lesions 
are characterized by luminal epithelial cells which are reduced in size and not fully 
differentiated into columnar secretory cells. PIA refers to focal atrophy lesions with 
vigorously proliferating epithelial cells that are associated with inflammation whereas 
atrophic lesions that are not associated with obvious inflammatory infiltrates are termed 
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proliferative atrophy (PA). However, both lesions have been proposed as precursors to 
both PIN and prostate cancer (True & Vakar-Lopez, 2011; Nelson & De Marzo, 2007). 
The prevalent form of prostatic neoplasms is adenocarcinoma. The degree of 
differentiation contributes largely to the aggressiveness of this disease rather than the 
size of the tumour (Kyprianou, 2014; Deneris & Huether, 2008). In the initial stage of 
prostate cancer, this disease is found to be relatively indolent with no clinical 
significance and essentially curable when confined to the prostatic capsule, such that 
most mortality of patients diagnosed with prostate cancer are due to other causes (Kumar 
et al., 2013; Abate-Shen & Shen, 2000). However, if this disease is not detected early 
and in an already aggressive form, prostate cancer will pose a significant threat to life or 
health, advancing from a locally invasive carcinoma to a metastatic stage resulting in 
mortality. The transition from localized to metastatic state is normally accompanied by a 
switch from androgen dependence to androgen independence condition (Abate-Shen & 
Shen, 2000).  
DHT, a potent intra-prostatic androgen, binds to the AR to induce activation of 
various target genes accountable for cell differentiation, proliferation and survival (Datta 
et al., 2011; Deneris & Huether, 2008). Although androgens are required for normal 
prostate development, they act as strong tumour promoters in prostate carcinogenesis 
through AR-mediated mechanisms (Deneris & Huether, 2008). AR is a 110 kDa 
phosphoprotein which belongs to the nuclear receptor superfamily (Kyprianou, 2012). 
The majority of AR molecules reside in the cytoplasm in an inactive form. The liganded 
AR translocates to the nucleus and binds to the promoter/enhancer region of the target 
genes leading to transcription and downstream effects. AR regulates gene expressions 
that stimulate cellular differentiation in prostate luminal epithelial cells, which is the 
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principal step of malignant transformation to prostate adenocarcinoma (Kyprianou, 
2012; Datta et al., 2011; Deneris & Huether, 2008). Androgen independence stage of 
prostate cancer may be caused by changes in AR, AR target genes, or AR signals (Held-
Warmkessel, 2007). The prostate cancer cells possess the ability to adapt to their 
extracellular microenvironment through alterations of  i) epithelial-stromal interactions; 
ii) pathophysiologic cellular stress responses; iii) growth factor-receptor pathways; 
and/or iv) the inflammatory response. This ability confers the cells the aptitude to 
survive in almost any microenvironments and, eventually, giving rise to aggressive 
phenotypes (Kyprianou, 2012).  
Prostate cancer cells have to travel via neurovascular bundles that lie adjacent to the 
prostate, as shown in Figure 2.4, in order to reach various metastatic sites, and must be 
able to adapt, survive and grow in varied microenvironments (Nelson & De Marzo, 
2007; Kirby & Brawer, 2004). Locally advanced prostate cancers often infiltrate the 
seminal vesicles and periurethral zones of the prostate and may subsequently invade the 
adjacent soft tissues, the wall of the urinary bladder, or, less commonly, the rectum. 
Distant metastases of prostate cancer are commonly occurring in the liver, lymph nodes, 
lungs, adrenals and bones; whereas in cases of  bone metastasis, the pelvis, ribs, femur, 
thoracic spine, lumbar spine, humerus and skull are the most common targets (Kumar et 
al, 2013; Deneris & Huether, 2008; Held-Warmkessel, 2007). Prostate cancer may 
metastasize and grow well in the bone because of the unique bone microenvironment 
enabling the cells to advance their aggressive phenotype by undermining the coordinated 
behaviour of osteoblasts and osteoclasts, thus producing destructive bony lesions, and, 
subsequently, spread malignant growth (Kyprianou, 2012; Nelson & De Marzo, 2007).   
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Figure 2.4: Human prostate cancer progression. Level 1 is the PIN stage, Level 2 is 
invasive carcinoma and Level 3 is metastatic stage (adapted from Kirby & Brawer, 
2004). 
 
 
 
 
 
 
 
 21 
2.3.3 Diagnosis, Grading and Staging 
Generally, an early detection of prostate cancer may improve many aspects in the 
management of prostate cancer patients such as the treatment, restricting the progression 
of cancer and prognosis. The first line of tests performed on patients who are suspected 
of having prostate cancer are the digital rectal examination (DRE) combined with 
measurement of serum PSA level (Philippou et al., 2014). DRE is a simple, fast and very 
cost-effective method in detecting prostate cancer. Since it is done by palpating, the 
tumour must be large enough and posteriorly situated as only the posterior portion of the 
gland is palpable by physician (Kirby & Brawer, 2004). In PSA blood test, the normal 
serum level for PSA is ≤ 4 ng/ml. However, one limitation of PSA is that while it is 
prostate-specific, it is not cancer specific (Kumar et al., 2013). Approximately 20% of 
patients were diagnosed with prostate cancer despite having a PSA level lower than 4 
ng/ml (van der Poel, 2007; Thompson et al., 2004), whereas in some cases, the PSA 
level may be elevated due to certain conditions such as benign prostatic hyperplasia 
(BPH), prostatitis, renal insufficiency, prostatic manipulation, irritation and recent 
ejaculation (Cheetham, 2014). These inadequacies may lead to over diagnosis and over 
treatment of the disease. As such, patients who have positive findings in digital rectal 
examination (DRE) and PSA tests is followed by more sophisticated diagnostic 
techniques, beginning with transrectal ultrasound (TRUS) and guided systemic biopsy, 
which enable the physician to locate the areas of abnormality (Philippou et al., 2014; 
Cheetham, 2014).  
Prostate cancer diagnosis is confirmed through microscopic examination of the 
tissue biopsy where the grade of the cancer, the number of cores positive for cancer and 
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percentage of cancer per core are able to be determined (Deneris & Huether, 2008; Ross 
et al., 2007). Other procedures such as computerized tomography (CT), magnetic 
resonance imaging (MRI), bone scans and lymphography are usually used if metastases 
are suspected to be in the lymph node, bone or other adjacent tissues (Deneris & 
Huether, 2008).   
The most widely used system for prostate cancer grading is the Gleason system. In 
this system, the pattern of infiltrating tumour glands is assigned a grade based on their 
level of aggressiveness from 1 (well differentiated) to 5 (poorly differentiated). As 
prostatic cancers are often heterogeneous (contain more than one pattern), a primary 
grade is assigned to the dominant pattern and the secondary grade to the next most 
frequent pattern. The sum of both values is considered the Gleason score (Table 2.1). 
This score provides useful prognostic information for the patients where the progressive 
loss of glandular differentiation is associated with worsening prognosis. Patients who are 
diagnosed with low Gleason score have an excellent prognosis while those with Gleason 
scores above 6 are associated with an alarming risk of escalating disease 
progression/aggressiveness, increased metastatic potential and diminished chance of 
survival (Epstein, 2015; Kumar et al., 2013; Ross et al., 2007; Kirby & Brawer, 2004).  
Prostate cancer staging is important as it describes the extent of disease spread and 
strongly correlates with prognosis. The treatment of prostatic cancer is determined 
primarily by the stage of the disease. The most common system used for prostate cancer 
staging is the American Joint Committee on Cancer (AJCC) tumour/node/metastases 
(TNM) system as shown in Table 2.2 (Buyyounouski et al., 2017; Ross et al., 2007).  
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Table 2.1: Histological definition of prostate cancer grading system and Gleason score 
(Epstein, 2015).  
Gleason score Histological characteristics 
Grade group 1:  
Gleason score < 6 
 
Only individual discrete well-formed glands 
Grade group 2:  
Gleason score 3+4=7 
Predominantly well-formed glands with lesser component of 
poorly formed / fused / cribriform glands 
 
Grade group 3:  
Gleason score 4+3=7 
Predominantly poorly formed / fused / cribriform glands with 
lesser component of well-formed glands 
 
Grade group 4:  
Gleason score 4+4=8; 
3+5=8; 5+3=8 
Only poorly formed / fused / cribriform glands  
Predominantly well-formed glands and lesser component 
lacking glands  
Predominantly lacking glands and lesser component of well-
formed glands 
 
Grade group 5:  
Gleason scores 9-10 
Lack gland formation (or with necrosis) with or without 
poorly formed / fused / cribriform glands 
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In TNM system, stages T1-T4 describe the pathological development of the tumour 
(Figure 2.5). T1 is assigned when the tumour is discovered by PSA testing or after 
transurethral resection of the prostate, and is not detectable by DRE or ultrasonography. 
Organ-confined palpable tumour is classified as T2 whereas tumour that palpably exceed 
beyond the prostate is classified as T3. T4 is assigned when the disease is at an advanced 
stage, in which the metastatic cancer infiltrates neighbouring organs. The nodal stages 
(N0-N1) and metastatic stages (M0-M1c) represent the disease clinical progression into 
the lymph nodes and other organs (Ross et al., 2007; Kirby & Brawer, 2004; 
Buyyounouski et al., 2017). For post-prostatectomy patients, a pathological T stage (pT) 
is often employed, in which there is no pT1 designation (Ross et al., 2007; 
Buyyounouski et al., 2017). Patients who are diagnosed at an early stage of prostate 
cancer at which the disease is still limited and confined to the prostate have better 
survival than those with disease that has spread beyond the gland (Held-Warmkessel, 
2007).  
2.3.4 Treatment 
Patients with prostate cancer maybe asymptomatic, if at early stage of disease, or 
may present with a variety of symptoms such as bladder outflow obstruction in local 
disease or hematuria, dysuria, anuria, hemospermia, impotence, incontinence, renal 
failure, and/or pain in the perineal, suprapubic, loin, bone and/or low back in locally 
invasive as well as metastatic disease (Kirby & Brawer, 2004). Thus treatment options 
of prostate cancer are both curative (eliminating the tumour or preventing cancer-related 
mortality) and palliative (relieving symptomatic conditions) and depend on several 
interrelating factors (Held-Warmkessel, 2007; Kirby & Brawer, 2004). 
